Effect of hepatitis C virus and its treatment on survival

The effect of hepatitis C virus (HCV) and its treatment on survival is not well defined. We undertook this study to determine the effect of HCV and its treatment on survival in a national cohort of HCV‐infected veterans and uninfected controls. We used a national sample of HCV‐infected persons and H...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hepatology (Baltimore, Md.) Md.), 2009-08, Vol.50 (2), p.387-392
Hauptverfasser: Butt, Adeel A., Wang, Xiaoqiang, Moore, Charity G.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 392
container_issue 2
container_start_page 387
container_title Hepatology (Baltimore, Md.)
container_volume 50
creator Butt, Adeel A.
Wang, Xiaoqiang
Moore, Charity G.
description The effect of hepatitis C virus (HCV) and its treatment on survival is not well defined. We undertook this study to determine the effect of HCV and its treatment on survival in a national cohort of HCV‐infected veterans and uninfected controls. We used a national sample of HCV‐infected persons and HCV‐uninfected controls from the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES) to compare survival between the two groups. We also compared the effect of treatment and treatment duration on survival in the HCV‐infected group. We used matched Cox proportional hazards model to determine the predictors of mortality. Kaplan‐Meier survival plots were generated to determine and compare survival among HCV‐infected and HCV‐uninfected persons, and among treated and untreated HCV‐infected persons.We identified 34,480 matched pairs of HCV‐infected subjects and controls. HCV infection was independently associated with a higher risk of mortality (hazards ratio, 1.37; 95% confidence interval, 1.31‐1.47). Subjects treated for 48 weeks or longer had the lowest mortality among HCV‐infected subjects (hazards ratio, 0.41; 95% confidence interval, 0.27‐0.64), whereas those who received less than 48 week of treatment had intermediate mortality (hazards ratio, 0.71 and 0.60 for 0‐23 weeks and 24‐47 weeks of treatment, respectively) compared with untreated subjects. Conclusion: HCV infection is associated with a substantial increase in mortality. Subjects who are initiated on treatment, and particularly those who proceed to finish a full course of treatment, have significantly reduced risk of mortality. Further studies are warranted to determine the effect of virological control on survival. (HEPATOLOGY 2009.)
doi_str_mv 10.1002/hep.23000
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67550732</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67550732</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4540-80c5d4de358af43927ef0b02dc05cc510f0e3b00be972bb4f7921f8a0904d7e3</originalsourceid><addsrcrecordid>eNp10L1OwzAUBWALgWgpDLwA8gISQ9prO8bxiKpCkSrB0N1yHFsY5afYSVHfnpREMDHd5dM5ugehawJzAkAX73Y3pwwATtCUcCoSxjicoilQAYkkTE7QRYwfPZApzc7RhEguCaHZFMmVc9a0uHG4T9Gtb33ES7z3oYtY1wX2bcRtsLqtbN2zGscu7P1el5fozOky2qvxztD2abVdrpPN6_PL8nGTmJSnkGRgeJEWlvFMu5RJKqyDHGhhgBvDCTiwLAfIrRQ0z1MnJCUu0yAhLYRlM3Q3xO5C89nZ2KrKR2PLUte26aJ6EJyDYLSH9wM0oYkxWKd2wVc6HBQBdZxJ9Q-qn5l6ezOGdnlliz857tKD2xHoaHTpgq6Nj7-OEpGRjB5LF4P78qU9_N-o1qu3ofob64l89g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67550732</pqid></control><display><type>article</type><title>Effect of hepatitis C virus and its treatment on survival</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Butt, Adeel A. ; Wang, Xiaoqiang ; Moore, Charity G.</creator><creatorcontrib>Butt, Adeel A. ; Wang, Xiaoqiang ; Moore, Charity G.</creatorcontrib><description>The effect of hepatitis C virus (HCV) and its treatment on survival is not well defined. We undertook this study to determine the effect of HCV and its treatment on survival in a national cohort of HCV‐infected veterans and uninfected controls. We used a national sample of HCV‐infected persons and HCV‐uninfected controls from the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES) to compare survival between the two groups. We also compared the effect of treatment and treatment duration on survival in the HCV‐infected group. We used matched Cox proportional hazards model to determine the predictors of mortality. Kaplan‐Meier survival plots were generated to determine and compare survival among HCV‐infected and HCV‐uninfected persons, and among treated and untreated HCV‐infected persons.We identified 34,480 matched pairs of HCV‐infected subjects and controls. HCV infection was independently associated with a higher risk of mortality (hazards ratio, 1.37; 95% confidence interval, 1.31‐1.47). Subjects treated for 48 weeks or longer had the lowest mortality among HCV‐infected subjects (hazards ratio, 0.41; 95% confidence interval, 0.27‐0.64), whereas those who received less than 48 week of treatment had intermediate mortality (hazards ratio, 0.71 and 0.60 for 0‐23 weeks and 24‐47 weeks of treatment, respectively) compared with untreated subjects. Conclusion: HCV infection is associated with a substantial increase in mortality. Subjects who are initiated on treatment, and particularly those who proceed to finish a full course of treatment, have significantly reduced risk of mortality. Further studies are warranted to determine the effect of virological control on survival. (HEPATOLOGY 2009.)</description><identifier>ISSN: 0270-9139</identifier><identifier>EISSN: 1527-3350</identifier><identifier>DOI: 10.1002/hep.23000</identifier><identifier>PMID: 19591128</identifier><identifier>CODEN: HPTLD9</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Antiviral Agents - therapeutic use ; Biological and medical sciences ; Case-Control Studies ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Hepatitis C - drug therapy ; Hepatitis C - mortality ; Humans ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Male ; Medical sciences ; Middle Aged ; United States - epidemiology ; Veterans</subject><ispartof>Hepatology (Baltimore, Md.), 2009-08, Vol.50 (2), p.387-392</ispartof><rights>Copyright © 2009 American Association for the Study of Liver Diseases</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4540-80c5d4de358af43927ef0b02dc05cc510f0e3b00be972bb4f7921f8a0904d7e3</citedby><cites>FETCH-LOGICAL-c4540-80c5d4de358af43927ef0b02dc05cc510f0e3b00be972bb4f7921f8a0904d7e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhep.23000$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhep.23000$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=21781822$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19591128$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Butt, Adeel A.</creatorcontrib><creatorcontrib>Wang, Xiaoqiang</creatorcontrib><creatorcontrib>Moore, Charity G.</creatorcontrib><title>Effect of hepatitis C virus and its treatment on survival</title><title>Hepatology (Baltimore, Md.)</title><addtitle>Hepatology</addtitle><description>The effect of hepatitis C virus (HCV) and its treatment on survival is not well defined. We undertook this study to determine the effect of HCV and its treatment on survival in a national cohort of HCV‐infected veterans and uninfected controls. We used a national sample of HCV‐infected persons and HCV‐uninfected controls from the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES) to compare survival between the two groups. We also compared the effect of treatment and treatment duration on survival in the HCV‐infected group. We used matched Cox proportional hazards model to determine the predictors of mortality. Kaplan‐Meier survival plots were generated to determine and compare survival among HCV‐infected and HCV‐uninfected persons, and among treated and untreated HCV‐infected persons.We identified 34,480 matched pairs of HCV‐infected subjects and controls. HCV infection was independently associated with a higher risk of mortality (hazards ratio, 1.37; 95% confidence interval, 1.31‐1.47). Subjects treated for 48 weeks or longer had the lowest mortality among HCV‐infected subjects (hazards ratio, 0.41; 95% confidence interval, 0.27‐0.64), whereas those who received less than 48 week of treatment had intermediate mortality (hazards ratio, 0.71 and 0.60 for 0‐23 weeks and 24‐47 weeks of treatment, respectively) compared with untreated subjects. Conclusion: HCV infection is associated with a substantial increase in mortality. Subjects who are initiated on treatment, and particularly those who proceed to finish a full course of treatment, have significantly reduced risk of mortality. Further studies are warranted to determine the effect of virological control on survival. (HEPATOLOGY 2009.)</description><subject>Antiviral Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Case-Control Studies</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Hepatitis C - drug therapy</subject><subject>Hepatitis C - mortality</subject><subject>Humans</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>United States - epidemiology</subject><subject>Veterans</subject><issn>0270-9139</issn><issn>1527-3350</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10L1OwzAUBWALgWgpDLwA8gISQ9prO8bxiKpCkSrB0N1yHFsY5afYSVHfnpREMDHd5dM5ugehawJzAkAX73Y3pwwATtCUcCoSxjicoilQAYkkTE7QRYwfPZApzc7RhEguCaHZFMmVc9a0uHG4T9Gtb33ES7z3oYtY1wX2bcRtsLqtbN2zGscu7P1el5fozOky2qvxztD2abVdrpPN6_PL8nGTmJSnkGRgeJEWlvFMu5RJKqyDHGhhgBvDCTiwLAfIrRQ0z1MnJCUu0yAhLYRlM3Q3xO5C89nZ2KrKR2PLUte26aJ6EJyDYLSH9wM0oYkxWKd2wVc6HBQBdZxJ9Q-qn5l6ezOGdnlliz857tKD2xHoaHTpgq6Nj7-OEpGRjB5LF4P78qU9_N-o1qu3ofob64l89g</recordid><startdate>200908</startdate><enddate>200908</enddate><creator>Butt, Adeel A.</creator><creator>Wang, Xiaoqiang</creator><creator>Moore, Charity G.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200908</creationdate><title>Effect of hepatitis C virus and its treatment on survival</title><author>Butt, Adeel A. ; Wang, Xiaoqiang ; Moore, Charity G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4540-80c5d4de358af43927ef0b02dc05cc510f0e3b00be972bb4f7921f8a0904d7e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Antiviral Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Case-Control Studies</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Hepatitis C - drug therapy</topic><topic>Hepatitis C - mortality</topic><topic>Humans</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>United States - epidemiology</topic><topic>Veterans</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Butt, Adeel A.</creatorcontrib><creatorcontrib>Wang, Xiaoqiang</creatorcontrib><creatorcontrib>Moore, Charity G.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Hepatology (Baltimore, Md.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Butt, Adeel A.</au><au>Wang, Xiaoqiang</au><au>Moore, Charity G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of hepatitis C virus and its treatment on survival</atitle><jtitle>Hepatology (Baltimore, Md.)</jtitle><addtitle>Hepatology</addtitle><date>2009-08</date><risdate>2009</risdate><volume>50</volume><issue>2</issue><spage>387</spage><epage>392</epage><pages>387-392</pages><issn>0270-9139</issn><eissn>1527-3350</eissn><coden>HPTLD9</coden><abstract>The effect of hepatitis C virus (HCV) and its treatment on survival is not well defined. We undertook this study to determine the effect of HCV and its treatment on survival in a national cohort of HCV‐infected veterans and uninfected controls. We used a national sample of HCV‐infected persons and HCV‐uninfected controls from the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES) to compare survival between the two groups. We also compared the effect of treatment and treatment duration on survival in the HCV‐infected group. We used matched Cox proportional hazards model to determine the predictors of mortality. Kaplan‐Meier survival plots were generated to determine and compare survival among HCV‐infected and HCV‐uninfected persons, and among treated and untreated HCV‐infected persons.We identified 34,480 matched pairs of HCV‐infected subjects and controls. HCV infection was independently associated with a higher risk of mortality (hazards ratio, 1.37; 95% confidence interval, 1.31‐1.47). Subjects treated for 48 weeks or longer had the lowest mortality among HCV‐infected subjects (hazards ratio, 0.41; 95% confidence interval, 0.27‐0.64), whereas those who received less than 48 week of treatment had intermediate mortality (hazards ratio, 0.71 and 0.60 for 0‐23 weeks and 24‐47 weeks of treatment, respectively) compared with untreated subjects. Conclusion: HCV infection is associated with a substantial increase in mortality. Subjects who are initiated on treatment, and particularly those who proceed to finish a full course of treatment, have significantly reduced risk of mortality. Further studies are warranted to determine the effect of virological control on survival. (HEPATOLOGY 2009.)</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>19591128</pmid><doi>10.1002/hep.23000</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0270-9139
ispartof Hepatology (Baltimore, Md.), 2009-08, Vol.50 (2), p.387-392
issn 0270-9139
1527-3350
language eng
recordid cdi_proquest_miscellaneous_67550732
source MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Antiviral Agents - therapeutic use
Biological and medical sciences
Case-Control Studies
Female
Gastroenterology. Liver. Pancreas. Abdomen
Hepatitis C - drug therapy
Hepatitis C - mortality
Humans
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Male
Medical sciences
Middle Aged
United States - epidemiology
Veterans
title Effect of hepatitis C virus and its treatment on survival
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T21%3A08%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20hepatitis%20C%20virus%20and%20its%20treatment%20on%20survival&rft.jtitle=Hepatology%20(Baltimore,%20Md.)&rft.au=Butt,%20Adeel%20A.&rft.date=2009-08&rft.volume=50&rft.issue=2&rft.spage=387&rft.epage=392&rft.pages=387-392&rft.issn=0270-9139&rft.eissn=1527-3350&rft.coden=HPTLD9&rft_id=info:doi/10.1002/hep.23000&rft_dat=%3Cproquest_cross%3E67550732%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67550732&rft_id=info:pmid/19591128&rfr_iscdi=true